Cargando…
Safety and Efficacy of the Complement Inhibitor AMY-101 in a Natural Model of Periodontitis in Non-human Primates
Periodontitis is a chronic inflammatory disease associated with overactivation of the complement system. Recent preclinical studies suggest that host-modulation therapies may contribute to effective treatment of human periodontitis, which may lead to loss of teeth and function if untreated. We previ...
Autores principales: | Kajikawa, Tetsuhiro, Briones, Ruel A., Resuello, Ranillo R.G., Tuplano, Joel V., Reis, Edimara S., Hajishengallis, Evlambia, Garcia, Cristina A.G., Yancopoulou, Despina, Lambris, John D., Hajishengallis, George |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5577415/ https://www.ncbi.nlm.nih.gov/pubmed/28879212 http://dx.doi.org/10.1016/j.omtm.2017.08.001 |
Ejemplares similares
-
Complement-Dependent Mechanisms and Interventions in Periodontal Disease
por: Hajishengallis, George, et al.
Publicado: (2019) -
The first case of COVID-19 treated with the complement C3 inhibitor AMY-101
por: Mastaglio, Sara, et al.
Publicado: (2020) -
Porphyromonas gingivalis disturbs host–commensal homeostasis by changing complement function
por: Olsen, Ingar, et al.
Publicado: (2017) -
Complement C3 inhibition in severe COVID-19 using compstatin AMY-101
por: Skendros, Panagiotis, et al.
Publicado: (2022) -
The purinergic receptor P2X5 contributes to bone loss in experimental periodontitis
por: Kim, Hyunsoo, et al.
Publicado: (2018)